ENOB News and Press, Enochian Biosciences Inc. From 02/24/20

FDA has granted Enochian an INTERACT meeting for its innovative approach to autologous stem cell transplantation as a potential cure for HIV. INTERACT is the first available FDA interaction and is a key step in the process towards an Investigational New Drug (IND) to study first-...

LOS ANGELES, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Enochian Biosciences, a company focused on gene-modified cellular therapy in infectious diseases and cancer, announces that it has finalized the acquisition of a novel Hepatitis B Virus (HBV) potential treatment or cure from Seraph Research Ins...

- Gregg Alton, the former interim CEO of Gilead Sciences, a company he served in many key roles during his more than 20 year tenure, and; - Carol Brosgart, MD, Clinical Professor of Medicine at the University of California, San Francisco (UCSF), former senior advisor on hepatitis fo...

Anti-retroviral therapy (ART), or highly-active-antiretroviral therapy (HAART), is effective in halting the progression of HIV infection (a disease affecting nearly 40 million persons worldwide). However, HAART does not cure the disease as the HIV virus, despite the treatment, remains hidden in ...

Anti-retroviral therapy (ART), or highly-active-antiretroviral therapy (HAART), is effective in halting the progression of HIV infection (a disease affecting nearly 40 million persons worldwide). However, HAART does not cure the disease as the HIV virus, despite the treatment, remains hidden in ...

A new gene therapy kills up to 98 percent of HBV infected cells but not uninfected cells .  Results from a commonly used mouse model to study HBV confirmed the HBV-infected cell-specific killing effect of the novel therapy.   Additional studies are underway. LOS...

Enochian Biosciences ( ENOB ) is hands down the craziest and most overvalued biotech that we’ve ever seen. Our initial report on Enochian has shaken things up within the company, and more developments have occurred that make the story even more bizarre. We discuss these new developm...

Gainers:  Paringa Resources (NASDAQ: PNRL ) +250% . More news on: Paringa Resources Limited, ASLAN Pharmaceuticals Limited, Hepion Pharmaceuticals, Inc., Stocks on the move, Read more ...

JanOne (NASDAQ: JAN ) +127%  on acquiring worldwide license for treatment of Peripheral Arterial Disease. More news on: JanOne Inc., Sorrento Therapeutics, Inc., The Medicines Company, Stocks on the move, Read more ...

Enochian Biosciences (NASDAQ: ENOB ) is up  18%  premarket on entering into an agreement in principle to acquire an exclusive, license for a treatment under development aimed to treat the Hepatitis B Virus (HBV) infections from G-Tech Bio, LLC. More news on: Enochian Bioscience...